TReatment for ImmUne Mediated PathopHysiology
What is the goal of the study?
This is a phase 2b, double-blind, tree arm, randomized, placebo controlled trial with restricted response adaptive randomization. The trial is designed to test the efficacy and safety of high dose methylprednisolone or equine anti-thymocyte globulin (eATG) as compared to supportive care alone for the treatment of acute liver failure in pediatric patients. The primary outcome will be survival with native liver at 21 days following study entry.
Who can participate in the study?
Please contact the study team listed below to learn more.